SASPEN Case Study by Prinsloo, A
96
SASPEN Case Study
2010;23(2)S Afr J Clin Nutr
Prinsloo A
Department of Health, South Africa
Correspondence to: Ms A Prinsloo, e-mail: annettep@ananzi.co.za
SASPEN Case Study
This case study was presented and discussed at the recent SASPEN 2010 Congress by Prof O Goulet, University of Paris Descartes. 
The summarised discussion of the proceedings was prepared by Annette Prinsloo.
Patient’s course
The patient was born at 39 weeks gestation, weighing 2 860 g. He was 
diagnosed with gastroschisis type III. He also presented with multiple 
intestinal atresias, a dilated duodenum and proximal jejunum as well 
as a left microcolon. On day 4 of life, the patient underwent surgery 
during which a small bowel resection and hemicolectomy were 
done. A jejunostomy, 30 cm from the ligament of Treitz, as well as a 
colostomy in the transverse colon were performed. On day 38 of life 
the patient developed a volvulus with subsequent jejunal necrosis 
leading to a perforation and resulting in peritonitis. This necessitated 
further surgery to create a new jejunostomy. On day 53 a jejuno-
colic anastomosis was performed. Post surgery a small bowel follow 
through study showed that the anastomosis was not functioning. 
On day 72 of life the anastomosis was redone. During this period, 
the patient developed recurrent episodes of catheter related sepsis 
and cholestasis. The patient was subsequently transferred to the 
Necker-Enfants Malades Hospital in France where a combined liver-
intestinal transplant was done. 
Diagnosis
Short bowel syndrome with cholestasis.
Anthropometry
The patient’s weight gain and growth was suboptimal during 
his clinical course. On admission to the Necker-Enfants Malades 
Hospital his weight was at -5SD and his length at -4SD.
Nutritional management 
Postoperatively parenteral nutrition in combination with enteral 
nutrition using an elemental (amino acid based) milk formula 
was given.
Discussion of case study
Growth of the small intestine reaches a peak at 25–35 weeks 
after conception, doubling in length during the last 15 weeks of 
pregnancy.1 Further rapid elongation takes place during the neonatal 
period until a crown-heel length of 60 cm is reached; after this, 
the rate of growth of the small intestine slows down until mature 
intestinal length is achieved at a body length of 100–140 cm.1
Short bowel syndrome (SBS) results from surgical resection, a 
congenital defect or disease-associated loss of absorptive capacity, 
and is characterised by the inability to maintain protein, energy, fluid, 
electrolyte and micronutrient balance when on a conventionally 
accepted normal diet.2,3  The most common causes of SBS include 
necrotising enterocolitis (NEC) and congenital malformations such as 
intestinal atresias, gastroschisis or midgut volvulus.3,4,5
Despite multiple attempts, the minimum small bowel length 
needed to facilitate normal absorption has not yet been defined.2 
The functional ability of the small bowel is determined by the 
intrinsic characteristics of the remainder of the small bowel post 
surgery.2  Patients at the greatest nutritional risk generally have a 
duodenostomy or a jejunoileal anastomosis with less than 35 cm 
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of residual small bowel, jejunocolic or ileocolic anastomosis with 
less than 60 cm of residual small bowel or an end jejunostomy with 
115 cm of residual small bowel.2
The goals in the treatment of infants with SBS are to keep the 
infant well nourished and growing proportionally, to keep fluid and 
electrolyte status stable, to minimise faecal loss of fluid, electrolytes 
and nutrients, and to maximise the process of bowel adaptation.3
The management of SBS is a multistage process.2 It begins with a 
process of total parenteral nutrition (TPN), followed by a combination 
of enteral feeds and parenteral nutrition (PN), continuous enteral 
feeding only, weaning to bolus feeding and solid foods, and finally 
dietary modification alone.2
The state, area, motility and length of remaining bowel predicts 
the infant’s ability to tolerate enteral nutrition.3 The dependence on 
total parenteral nutrition (TPN) depends on the remaining length of 
bowel and the presence of the ileo caecal valve (ICV).3  The process 
of bowel adaptation is the key to achieving independence from TPN. 
Adaptation is characterised by cellular hyperplasia, villus hypertrophy 
and increased crypt depth and bowel dilation.3 This process may 
begin almost 24–48 hours post resection, and may continue for 
months to years. Some of the factors associated with adaptation 
include epidermal growth factor, GLP-2, glutamine, growth hormone 
and long chain polyunsaturated fatty acids from fish oils.3
Long term TPN is associated with the development of intestinal 
failure associated liver disease (IFALD), comprising hepatic steatosis, 
cholelithiasis or hepatic fibrosis.3,5,6 Cholestasis is common amongst 
infants receiving PN from birth onward. Multifactorial risk factors 
have been implicated in the development of TPN-associated 
cholestasis, including prematurity, low birth weight, duration of TPN, 
multiple surgical procedures, recurrent sepsis, excessive energy 
intake, excessive protein and excessive parenteral lipids, lack of 
enteral feeding, systemic or portal endotoxaemia, reduced levels of 
gastrointestinal hormones, as well as the presence of phytosterols in 
intravenous fat emulsions.3,6 
Commercially available intravenous fat emulsions are soy based 
preparations containing phytosterols such as sitosterol, campesterol 
and sigmasterol.6 The observation of high plasma levels of 
phytosterols in patients with TPN-associated cholestasis receiving 
intravenous fat emulsions led to the hypothesis that accumulation 
of these substances contributes to cholestasis.2,6 Their intravenous 
route of administration can lead to their accumulation in the 
hepatocyte because they are inefficiently metabolised by the liver.6 
Incorporation into hepatocyte membranes can then affect membrane 
fluidity and membrane-bound transport proteins such as the 
canalicular adenosine triphosphate-dependant bile acid transporters 
and sodium potassium-adenosine triphosphate.6 Evidence from both 
animal and clinical studies indicates that omega-3 polyunsaturated 
fatty acids and their specific lipid mediators can reduce not only the 
activity of inflammatory processes but may also lower inflammatory 
susceptibility in general.6 Thus, they can also lessen the inflammatory 
response in liver tissue probably by regulating Kupffer cell activation 
and suppressing cytokine production.6 Omega-3 supplementation 
in addition to conventional lipids (to prevent essential fatty acid 
deficiency) may be advantageous in the prevention and treatment of 
TPN-associated cholestasis.3,6
Prevention of IFALD can be achieved by limiting total energy overload.2 
Excessive non-protein energy has been associated with increased 
sepsis risk. The risk of sepsis may be a result of hyperinsulinism 
and hyperglycaemia, the facilitation of bacterial growth in a lipid 
rich solution, or an increased propensity for bacterial translocation.3 
TPN with excessive glucose intake may induce insulin resistance 
and subsequent steatosis.2  Furthermore, IFALD can be prevented by 
using parenteral solutions containing taurine.2,5 Taurine increases 
bile flow and protects against toxic bile salts, such as lithocholic acid, 
which has been shown to produce bile duct hyperplasia, gallstone 
formation and intrahepatic cholestasis. Other worthwhile strategies 
to prevent IFALD include intermittent infusion of TPN,2 prevention of 
other catheter-related sepsis and reduction of intra-luminal bacterial 
overgrowth.5
Lack of enteral nutrition with a subsequent reduction of 
gastrointestinal hormones such as cholecystokinin, motilin, 
glucose dependant insulinotropic polypeptide, secretin, pancreatic 
polypeptide, glucagons and vasoactive intestinal peptide may 
reduce gallbladder contractibility and the development of intestinal 
stasis.2  Disrupted enterohepatic circulation caused by ileal disease, 
resection and lack of enteral nutrition with a subsequent reduction 
of hepatocellular bile acid, bile secretion, and gallbladder contraction 
increases the likelihood of progressive liver injury.2
In a recent study done on  TPN-dependant infants (N = 10) with 
SBS, Cole and co-workers studied the impact of feeding route and 
intestinal permeability on blood stream infection (BSI), small bowel 
bacterial overgrowth (SBBO) and systemic immune responses.4  They 
found that BSI incidence was high (80%) and SBBO was common 
(50%). SBBO increased the odds for BSI (> 7-fold; p = 0.009).4 
Serum TNF-α and interleukin-1 ß, -6, and -8 levels diminished 
with increased enteral nutrition.4 The authors thus concluded that 
in children with SBS, SBBO increases the risk for BSI, and systemic 
proinflammatory response decreases with increasing enteral feeding 
and weaning of TPN.4
In general, SBBO is a complication that frequently occurs after 
resection of the ileocaecal valve, when a tight anastomosis is 
present or with poor motility of a dilated small bowel segment. 
It is responsible for mucosal inflammation which can lead to 
nutrient malabsorption and a depleted bile acid pool. This results in 
steatorrhoea and malabsorption of fat-soluble vitamins.5
Aggressive enteral nutrition ensuring at least 20–30% of total daily 
energy intake through the enteral route promotes enterohepatic 
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gut hormones.2 The choice of an appropriate enteral feed continues 
to be debated in the literature and has not been determined yet. 
Colostrum and breast milk may offer some advantages when 
available.3 In animal models, colostrum and colostrum protein 
concentrate have been shown to stimulate mucosal growth.  Whether 
the same results will be achieved with pasteurised donor breast milk 
need to be investigated.3 Amino acid based and protein hydrolysate 
formulae have traditionally been used to shorten the duration of 
TPN.3 The calcium and phosphorus content of these formulae may 
not be ideal, but they are typically better than that which can be 
delivered by TPN.3
The ileocaecal valve (ICV), located between the small and large bowel, 
acts to slow the transit time of intestinal contents and bacteria into 
the ileum.3  Bacterial colonisation of the small bowel, in the absence 
of the ICV, can reduce absorption of vitamin B12, deconjugate bile 
salts, reduce bile salt absorption, and impair gut function.2,3  With 
the preservation of the ICV, it would be reasonable to expect that 
the absorption of fluid or nutrients would improve by delaying the 
transit time of the intestinal contents.2 This concept has not been 
supported by experimental evidence.2 In cases of SBBO carbohydrate 
restriction, an increase in fat and protein intake is useful to decrease 
the development of gas-related symptoms and osmotic diarrhoea, 
because most bacteria ferment only carbohydrate. In patients with 
significant bile acid losses, a high fat diet may increase stool output 
and increase risk of oxalate nephropathy.2
During transition from TPN to enteral nutrition careful attention 
should be paid to monitoring serum electrolytes and hydration 
status.2 Excessive osmotic fluid is the most common cause of 
diarrhoea.2 Normal or half normal saline, as well as different 
intravenous electrolytes (potassium, sodium and bicarbonate) can 
be added to the patient’s formula to meet their fluid and electrolyte 
requirements.2 Continuous enteral nutrition as well as the use 
of diluted enteral formulae could also be employed to maintain 
adequate electrolyte and hydration status.2
Achievement of normal developmental goals is often overlooked 
in children with SBS. In an attempt to optimise nutritional intake 
various strategies are used including TPN as well as alternative 
feeding routes such as nasogastric tubes and gastrostomies. Oral 
intake is usually delayed, which could lead to feeding difficulties 
later in life. Non-nutritive, oral motor therapy and early oral feedings 
are important in intestinal rehabilitation.3 An oral motor stimulation 
programme should be initiated when feasible and early small enteral 
feeds should be given orally when developmentally appropriate 
and safe.3
The following factors contributed to the clinical course of the patient:
• The lack of breastfeeding after birth deprived the patient of 
the immunological factors which were needed to support his 
immune system.
• The loss of the ICV created the ideal environment for SBBO, 
which contributed to recurrent episodes of sepsis.
• Aggressive continuous enteral nutrition predisposed the patient 
to the development of complications e.g. volvulus and jejunal 
necrosis.
• Long term TPN with high osmolar intravenous solutions led to 
vascular thrombosis.
• Continuous TPN, with an excessive glucose intake, reduced lipid 
intake, lack of additional α-tocopherol and possible aluminium 
contamination lead to repeated episodes of cholestasis.
In retrospect, Professor Goulet concluded that the ideal treatment 
for this patient, as supported by the literature, would have been 
intermittent TPN containing an omega-3 lipid infusion. Oral feeding 
using either breastmilk or a protein hydrolysate formula should have 
been instituted timeously. A liver transplant could have been avoided. 
By reversing the cholestasis and improving the patient’s nutritional 
status, an isolated intestinal transplant could have been done.
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